Related Experiment Video
Updated: May 16, 2026

Functional Assessment of Kinesin-7 CENP-E in Spermatocytes Using In Vivo Inhibition, Immunofluorescence and Flow Cytometry
Published on: December 28, 2021
FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57
Rolando Cuevas1, Nina Korzeniewski, Yanis Tolstov
1Cancer Virology Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
Abstract:
Malignant tumors with deregulated FGF-2 expression such as prostate cancer are also frequently aneuploid. Aneuploidy can be caused by cell division errors due to extra centrosomes and mitotic spindle poles. However, a link between FGF-2 overexpression and chromosome missegregation has so far been elusive. Here, we show that FGF-2 rapidly uncouples centrosome duplication from the cell division cycle in prostate cancer cells through CEP57, an intracellular FGF-2-binding and trafficking factor. CEP57 was initially identified as a regulator of centriole overduplication in an RNA interference screen. We subsequently found that CEP57 rapidly stimulates centriole overduplication and mitotic defects when overexpressed and is required not only for FGF-2-induced centriole overduplication but also for normal centriole duplication. We provide evidence that CEP57 functions by modulating tubulin acetylation, thereby promoting daughter centriole stability. CEP57 was found to be overexpressed on the mRNA and protein level in a subset of prostate cancers, of which the vast majority also showed FGF-2 upregulation. Taken together, our results show an unexpected link between altered microenvironmental signaling cues such as FGF-2 overexpression and mitotic instability and provide a rationale for the therapeutic targeting of the FGF-2/FGFR1/CEP57 axis in prostate cancer. Cancer Res; 73(4); 1400-10. ©2012 AACR.
Insights
Fibroblast growth factor 2 (FGF-2) overexpression causes prostate cancer cells to mismanage centrosome duplication via CEP57, leading to aneuploidy. Targeting the FGF-2/FGFR1/CEP57 pathway may offer new prostate cancer therapies.
Area of Science:
- Cell Biology
- Cancer Biology
- Molecular Oncology
Background:
- Malignant tumors, including prostate cancer, often exhibit aneuploidy, a condition linked to errors in cell division.
- The precise mechanisms connecting fibroblast growth factor 2 (FGF-2) overexpression to chromosome missegregation have remained unclear.
Purpose of the Study:
- To investigate the link between FGF-2 overexpression and aneuploidy in prostate cancer.
- To elucidate the role of CEP57 in FGF-2-mediated centrosome duplication and mitotic instability.
Main Methods:
- Utilized RNA interference screening to identify factors regulating centriole duplication.
- Examined the effects of FGF-2 and CEP57 overexpression on centrosome duplication and cell division in prostate cancer cells.
- Assessed tubulin acetylation levels and CEP57 expression in prostate cancer tissues.
Main Results:
- FGF-2 rapidly decouples centrosome duplication from the cell cycle through CEP57.
- CEP57 overexpression leads to centriole overduplication and mitotic defects.
- CEP57 modulates tubulin acetylation, influencing daughter centriole stability.
- CEP57 is overexpressed in a subset of prostate cancers with concurrent FGF-2 upregulation.
Conclusions:
- Demonstrates an unexpected link between FGF-2 signaling and mitotic instability in prostate cancer.
- Identifies CEP57 as a key mediator of FGF-2-induced centrosome abnormalities.
- Suggests the FGF-2/FGFR1/CEP57 axis as a potential therapeutic target for prostate cancer.
Related Concept Videos
Abnormal Proliferation
Mitogens and the Cell Cycle
Anaphase Promoting Complex
Separation of Sister Chromatids
At the onset of anaphase, separase, a proteolytic enzyme, is...
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Negative Regulator Molecules

